Stemline Therapeutics (STML +10%) moves up again today after being initiated at Ladenburg...

|About: Stemline Therapeutics (STML)|By:, SA News Editor

Stemline Therapeutics (STML +10%) moves up again today after being initiated at Ladenburg Thalmann with a Buy rating and a hefty $36 price target. The stock has been moving steadily higher over the past few weeks, after the FDA granted an Orphan Drug Designation to its treatment for blastic plasmacytoid dendritic cell neoplasm, SL-401.